

Department Seminars

Observational Medical Outcomes
Partnership: Improving drug safety
through data mining of observational
healthcare databases



Patrick Ryan
GlaxoSmithKline R & D

David Madigan
Dept. of Statistics, Columbia University

Abstract:

Drug safety continues to be a major public health concern in the United States, with adverse drug reactions ranking as the 4th to 6th leading cause of death, and resulting in health care costs of \$3.6 billion annually. Recent media attention and public scrutiny of high-profile drug safety issues have increased visibility and skepticism of the effectiveness of the current post-approval safety surveillance processes.

Recent calls have been made to establish a national active drug safety surveillance system that leverages observational data, including administrative claims and electronic health records, to monitor and evaluate potential safety issues of medicines. However, the development and evaluation of appropriate statistical methods for observational data have not yet been studied. This presentation will highlight the opportunities and challenges for applying data mining to observational healthcare databases, and discuss the potential role of exploratory analysis in better understanding the effects of medicines.

SPECIAL SEMINAR

Tuesday,
Sept 22, 2009

7615 MSC

10:00-11:00 a.m.

Seminars sponsored by the Department of



Biostatistics & Medical Informatics